Medical Device News Magazine

Sustained Acoustic Medicine Device sam® Offers an Alternative Solution to Pain Medication and Surgery

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

JUNE 9, 2020

Sustained acoustic medicine device (sam®) from ZetrOZ Systems offers physicians and orthopedic surgeons an alternative solution to pain medication and surgery for their patients.

Medical providers can prescribe sam®, the only FDA-cleared long-duration ultrasound device, for prescription home-use to treat arthritis and soft tissue injuries.

sam® is a non-invasive prescription medical device that is applied over the target injury and delivers a localized treatment. The device is an excellent option for avoiding medication and delaying surgery, as well as improving postoperative healing and surgical outcomes. sam® is especially beneficial for patients who struggle with poor healing capability.

In addition to accelerating and improving the healing process, sam® is also a very effective treatment for pain arising from conditions such as arthritis, back spasms, disk herniation and tendonitis.

Sixty million people suffer from arthritis and 50 million people struggle with back pain in the United States alone. The leadership team at ZetrOZ Systems set a goal to help 100 million patients who are in pain or facing surgery. sam® does not block or mask pain. The device treats the damaged tissue and inflammatory response that causes it, getting to the root of the problem. ZetrOZ Systems believes that not all patients require surgery or medication.

“We want physicians and orthopedic surgeons to know they are not limited in the options they can offer patients. sam® gives them a viable, convenient alternative to prescribing drugs or putting patients under the knife,” said Dr. George Lewis, chief executive officer of ZetrOZ Systems.

While sam® is technologically sophisticated, it is also easy to use and apply, making it the perfect choice for home application by patients. The solution is convenient, as patients can engage in most activities while wearing it. sam® ships directly to the patient’s home, conserving clinic time and requiring little followup from medical providers.

Medical providers can prescribe sam® using a simple Rx form available at samrecover.com. Patients typically undergo treatment for eight to 10 weeks. Each treatment includes the sam® device and five to eight packs of ultrasound coupling patches. Those with chronic arthritis pain will continue to use the device beyond 10 weeks to maintain their condition.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”